News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Welichem Biotech Inc. (WBI.V) Completes Phase IIa Clinical Trial on Eczema


6/20/2008 12:20:11 PM

BURNABY, BC, June 19 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX- V: WBI), a biotechnology company developing therapeutic drugs for the treatment of anti-inflammatory and auto-immune diseases and cancer, is pleased to announce that the clinical component of a Phase IIa trial on Atopic Dermatitis (a form of eczema) has been completed. The final report on this randomized, double-blinded, vehicle-controlled study to evaluate the safety, tolerability and efficacy of topically applied WBI-1001 cream in subjects with Atopic Dermatitis (AD) is expected later this summer.

Read at Canada NewsWire

comments powered by Disqus
   
Eczema

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES